Michael Meekins has led research and development at TAE since 2019, shaping the talented engineering department tasked with designing and building the company’s groundbreaking fusion research reactors and cancer treatment technologies.

Michael joined TAE in 2005 and laid the foundation of the engineering department before being invited to join the international nuclear fusion research and engineering project ITER, headquartered in Saint-Paul-lez-Durance, France. After five years there, Michael returned to TAE to build the C-2W machine in 2015.

Michael has also coordinated the engineering, fabrication and installation of TAE Life Sciences’ medical particle accelerator, part of the Boron Neutron Capture Therapy (BNCT) for cancer treatment, in Novosibirsk, Russia and Xiamen, China.

Michael brings a wealth of expertise and experience to TAE, with training in nuclear fusion safety analysis, risk management, program management, fabrication of ultra-high vacuum equipment, high consequence rigging and lifting, welding, machining and advanced manufacturing techniques. He is named in numerous patents and has had his research published in respected journals, including Physics of Plasmas, Structural Engineering International, Physics Procedia, and Physical Review Letters.

Prior to joining TAE, Michael worked for Lockheed Martin and Archimedes Technology Group.

Michael earned a B.S. in aerospace engineering from the University of California, Los Angeles.